Zheng L - Search Results

1

Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.

Xu Y, Kong W, Cao M, Wang J, Wang Z, Zheng L, Wu X, Cheng R, He W, Yang B, Dong B, Pan J, Chen Y, Huang J, Jiang C, Zhai W, Li F, Chen R, Zhou X, Wu G, Geng X, Chen J, An H, Yuan Y, Xu T, Chen D, Lin D, Xu L, Huang K, Peng L, Yu Y, Tai S, Qi H, Luo K, Kang X, Wang H, Huang Y, Zhang J, Xue W. Xu Y, et al. Among authors: zheng l. Eur Urol. 2023 Feb;83(2):163-172. doi: 10.1016/j.eururo.2022.05.029. Epub 2022 Jun 15. Eur Urol. 2023. PMID: 35715365

2

Oncogenic β-catenin stimulation of AKT2-CAD-mediated pyrimidine synthesis is targetable vulnerability in liver cancer.

Liu F, Gai X, Wu Y, Zhang B, Wu X, Cheng R, Tang B, Shang K, Zhao N, Deng W, Chen J, Zhang Z, Gu S, Zheng L, Zhang H. Liu F, et al. Among authors: zheng l. Proc Natl Acad Sci U S A. 2022 Sep 27;119(39):e2202157119. doi: 10.1073/pnas.2202157119. Epub 2022 Sep 19. Proc Natl Acad Sci U S A. 2022. PMID: 36122209 Free PMC article.

3

Absence of terminal deoxynucleotidyl transferase expression in T-ALL/LBL accumulates chromosomal abnormalities to induce drug resistance.

Xiao H, Wang S, Tang Y, Li S, Jiang Y, Yang Y, Zhang Y, Han Y, Wu X, Zheng L, Li Y, Gao Y. Xiao H, et al. Among authors: zheng l. Int J Cancer. 2023 Jun 1;152(11):2383-2395. doi: 10.1002/ijc.34465. Epub 2023 Feb 22. Int J Cancer. 2023. PMID: 36757202

4

Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.

Zheng L, Xiong A, Wang S, Xu J, Shen Y, Zhong R, Lu J, Chu T, Zhang W, Li Y, Zheng X, Han B, Zhong H, Nie W, Zhang X. Zheng L, et al. Among authors: zheng x. Front Immunol. 2023 Jan 26;14:1094378. doi: 10.3389/fimmu.2023.1094378. eCollection 2023. Front Immunol. 2023. PMID: 36776882 Free PMC article.

5

Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma.

Zheng L, Zhu ZR, Sneh T, Zhang WT, Wang ZY, Wu GY, He W, Qi HG, Wang H, Wu XY, Fernández-García J, Abramovich I, Xu YZ, Zhang J, Gottlieb E. Zheng L, et al. J Clin Invest. 2023 Jun 1;133(11):e165028. doi: 10.1172/JCI165028. J Clin Invest. 2023. PMID: 37053010 Free PMC article.

6

Fumarate induces LncRNA-MIR4435-2HG to regulate glutamine metabolism remodeling and promote the development of FH-deficient renal cell carcinoma.

Zhu L, Hong Y, Zhu Z, Huang J, Wang J, Li G, Wu X, Chen Y, Xu Y, Zheng L, Huang Y, Kong W, Xue W, Zhang J. Zhu L, et al. Among authors: zheng l. Cell Death Dis. 2024 Feb 19;15(2):151. doi: 10.1038/s41419-024-06510-2. Cell Death Dis. 2024. PMID: 38374146 Free PMC article.

7

Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.

Sang Y, Hou Y, Cheng R, Zheng L, Alvarez AA, Hu B, Cheng SY, Zhang W, Li Y, Feng H. Sang Y, et al. Among authors: zheng l. Neuro Oncol. 2019 Nov 4;21(11):1423-1435. doi: 10.1093/neuonc/noz107. Neuro Oncol. 2019. PMID: 31232447 Free PMC article.

8

Transketolase promotes MAFLD by limiting inosine-induced mitochondrial activity.

Tong L, Chen Z, Li Y, Wang X, Yang C, Li Y, Zhu Y, Lu Y, Liu Q, Xu N, Shao S, Wu L, Zhang P, Wu G, Wu X, Chen X, Fang J, Jia R, Xu T, Li B, Zheng L, Liu J, Tong X. Tong L, et al. Among authors: zheng l. Cell Metab. 2024 May 7;36(5):1013-1029.e5. doi: 10.1016/j.cmet.2024.03.003. Epub 2024 Mar 27. Cell Metab. 2024. PMID: 38547864

9

Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer.

Zheng L, Hu F, Huang L, Lu J, Yang X, Xu J, Wang S, Shen Y, Zhong R, Chu T, Zhang W, Li Y, Zheng X, Han B, Zhong H, Nie W, Zhang X. Zheng L, et al. Among authors: zheng x. J Immunother Cancer. 2024 Apr 18;12(4):e008190. doi: 10.1136/jitc-2023-008190. J Immunother Cancer. 2024. PMID: 38641349 Free PMC article.

10

Molecular mechanism of c-Myc and PRPS1/2 against thiopurine resistance in Burkitt's lymphoma.

Li T, Song L, Zhang Y, Han Y, Zhan Z, Xv Z, Li Y, Tang Y, Yang Y, Wang S, Li S, Zheng L, Li Y, Gao Y. Li T, et al. Among authors: zheng l. J Cell Mol Med. 2020 Jun;24(12):6704-6715. doi: 10.1111/jcmm.15322. Epub 2020 May 11. J Cell Mol Med. 2020. PMID: 32391636 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15,329 results

Search Page